Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
10 studies found for:    "membranoproliferative glomerulonephritis type II" OR "Glomerulonephritis, Membranoproliferative"
Show Display Options
RSS Create an RSS feed from your search for:
"membranoproliferative glomerulonephritis type II" OR "Glomerulonephritis, Membranoproliferative"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis Type II;   C3 Glomerulonephritis
Intervention: Drug: CDX-1135
2 Unknown  Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
3 Completed Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Intervention: Drug: Rituximab
4 Withdrawn Sulodexide Treatment in Patients With Dense Deposit Disease
Condition: Dense Deposit Disease
Intervention: Drug: Sulodexide
5 Active, not recruiting Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
6 Withdrawn TP10 Use in Patients With C3 Glomerulopathy (C3G)
Condition: Dense Deposit Disease
Intervention: Drug: TP10
7 Not yet recruiting Daratumumab in Treatment of PGNIMD and C3 GN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Daratumumab
8 Not yet recruiting A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
Conditions: C3 Glomerulonephritis;   Dense Deposit Disease;   Membranoproliferative Glomerulonephritis, Type II;   C3 Glomerulopathy;   Immune Complex Mediated Membranoproliferative Glomerulonephritis
Intervention: Drug: ACH-0144471
9 Completed BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
Conditions: Glomerulonephritis, Membranoproliferative;   Lupus Nephritis
Intervention: Drug: BG9588
10 Recruiting Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Conditions: IgAN;   Lupus Nephritis;   MN;   C3G
Interventions: Biological: OMS721;   Other: Vehicle (D5W)

Study has passed its completion date and status has not been verified in more than two years.